Cerebro Spinal Fluid Collection (CSF)

Sponsor
University Hospital, Strasbourg, France
Study ID
NCT04844060
Status
Recruiting
Apply to this trial

Conditions

  • Alzheimer Disease
  • Dementia With Lewy Bodies
  • Frontotemporal Dementia
  • Multiple System Atrophy
  • Parkinson's Disease Dementia

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

  • Lumbar punction — OTHER
    Lumbar punction

Study Details

Cognitive neurodegenerative diseases are a major public health issue. At present, the diagnosis of certainty is still based on anatomopathological analyses. Even if the diagnostic tools available to clinicians have made it possible to improve probabilistic diagnosis during the patient's lifetime, there are still too many diagnostic errors and sub-diagnostic in this field. The arrival of biomarkers has made it possible to reduce these diagnostic errors, which were of the order of 25 to 30%. This high error rate is due to different parameters. These diseases are numerous and often present common symptoms due to the fact that common brain structures are affected. These diseases evolve progressively over several years and their early diagnosis, when the symptoms are discrete, makes them even more difficult to diagnose at this stage. In addition, co-morbidities are common in the elderly, further complicating the diagnosis of these diseases. At present, the only cerebrospinal fluid (CSF) biomarkers that are routinely used for the biological diagnosis of neurodegenerative cognitive pathologies are those specific to Alzheimer's disease: Aβ42, Aβ40, Tau-total and Phospho-Tau. These biomarkers represent an almost indispensable tool in the diagnosis of dementia. It is therefore important to determine whether Alzheimer's biomarkers can be disrupted in other neurodegenerative cognitive pathologies, but also to find biomarkers specific to these different pathologies by facilitating the implementation of clinical studies which will thus make it possible to improve their diagnosis.

Key Dates

First listed
Apr 14, 2021
Start date
Feb 28, 2010
Status verified
Apr 2023
Primary completion
Dec 31, 2030
Completion
Dec 31, 2030

Study Design

Enrollment
10,000 participants (estimated)

Arms

  • Arm: Patients with cognitive impairment
    All patients with cognitive disorders observed at the memory center of Strasbourg and in whom a lumbar puncture is performed as part of the patient's diagnosis.

Primary Outcome Measure

CSF collection [ Time Frame: 1 year ]

Central Contacts

Find similar trials

Nationwide
Alzheimer's disease trialsNeurology trialsDementia care trialsBrain disorders trialsGeriatrics trials

Related Studies